News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

KaloBios Pharmaceuticals, Inc. to Present at 2013 JMP Securities Healthcare Conference


7/3/2013 6:27:31 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif., July 2, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will present at the 2013 JMP Securities Healthcare Conference on July 10 in New York City. KaloBios President and Chief Executive Officer, David W. Pritchard, will provide an overview of KaloBios and the company's three current clinical programs for its proprietary, patient-targeted monoclonal antibody therapeutics.

(Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO)

Company Presentation:
When: Wednesday July 10, 2013, 12:00 PM EDT
Where: The St. Regis Hotel, New York City, NY

Webcast:
To access the live and archived audio webcast of the JMP Securities presentation please log on through a link located in the Investors section of the KaloBios Pharmaceuticals, Inc. website under the Events & Presentations tab: http://wsw.com/webcast/jmp21/KBIO.

A replay of the webcast will be available one hour after the conclusion of the live event.

About KaloBios
KaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat severe medical conditions with a primary clinical focus on respiratory diseases and cancer. For more information on KaloBios Pharmaceuticals, Inc., please visit our web site at http://www.kalobios.com.

Contact:

Jeffrey H. Cooper
Chief Financial Officer
KaloBios Pharmaceuticals, Inc.
(650) 243-3146
ir@kalobios.com

Media Contact:

Joan E. Kureczka
Kureczka/Martin Associates
Tel: (415) 821-2413
Mobile: (415) 690-0210
Joan@Kureczka-Martin.com

SOURCE KaloBios Pharmaceuticals, Inc.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES